Drug Profile
DITPA - Zarion Pharmaceuticals
Alternative Names: 3,5-diiodothyropropionic acid - Zarion PharmaceuticalsLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Zarion Pharmaceuticals
- Class Cardiotonics; Diiodothyronines; Propionic acids; Small molecules
- Mechanism of Action Thyroid hormone modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Allan-Herndon-Dudley syndrome
Most Recent Events
- 03 Mar 2014 Phase-II clinical trials in Allan-Herndon-Dudley syndrome in Australia (PO)
- 14 May 2013 DITPA - Zarion Pharmaceuticals receives Orphan Drug status for Allan-Herndon-Dudley syndrome in USA